# Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy

Study · id `cardio:ct-nct02172040` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02172040](<https://clinicaltrials.gov/study/NCT02172040>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02172040

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.

## Technical summary

Registry record NCT02172040. Randomized; triple masking; primary purpose treatment. Start 2014-06-26 (actual); primary completion 2015-11-19 (actual). Results posted on 2017-10-03.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 152 participants (enrolled count; ClinicalTrials.gov record NCT02172040, source copy `cardio:ctgov-nct02172040-2018-10-10`, retrieved 2026-10-26)
- Started: 2014-06-26 (actual) (ClinicalTrials.gov record NCT02172040, source copy `cardio:ctgov-nct02172040-2018-10-10`, retrieved 2026-10-26)
- Primary completion: 2015-11-19 (actual) (ClinicalTrials.gov record NCT02172040, source copy `cardio:ctgov-nct02172040-2018-10-10`, retrieved 2026-10-26)
- Completion: 2015-11-19 (actual) (ClinicalTrials.gov record NCT02172040, source copy `cardio:ctgov-nct02172040-2018-10-10`, retrieved 2026-10-26)
- Results first posted: 2017-10-03 (ClinicalTrials.gov record NCT02172040, source copy `cardio:ctgov-nct02172040-2018-10-10`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT02172040, source copy `cardio:ctgov-nct02172040-2018-10-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02172040-2018-10-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy
- Condition: Hypertension
- Intervention (Drug): Over-encapsulated 10 mg amlodipine besylate tablet
- Intervention (Drug): Matched placebo capsule for over-encapsulated celecoxib capsule
- Intervention (Drug): Over-encapsulated 200 mg celecoxib capsule
- Intervention (Drug): Matched placebo capsule for over-encapsulated amlodipine besylate tablet
- Lead sponsor: Kitov Pharmaceuticals, Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 6e803c5b77634947d66313598e30b3b1c3dc50a833ab4eab1e2ac4332b628cde
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
